Investigational immunotherapies offer bright prospects in advanced melanoma

ASCO Chicago 2013: Inspired by the 2011 approval of ipilimumab the immunotherapy paradigm is experiencing a fervent revival in metastatic melanoma. Three novel strategies provoke the body’s immune system to attack melanomas are enabling patients to live better and longer with their disease. Read more.